Quick Connect

White Paper

Product Alert – Daprodustat

Product Alert – Daprodustat

Daprodustat is a potent reversible inhibitor of hypoxia-inducible factor (HIF)-prolyl hydroxylase (PH) 1, PH2 and PH3, with an IC50 in the low nM range. By inhibiting HIF-PHDs, Daprodustat promotes the stabilisation and nuclear accumulation of HIF-1α and HIF-2α transcription factors.

Dr. Reddy's API Offering*

Targeting CS01 form - Lab samples and COA are available.

  • Reliable KSM suppliers were added to ensure timely deliveries and adherence to stringent specifications.
  • We are planning adequate capacity to supply development quantity in a short lead time.
  • cGMP API manufacturing facilities, successfully inspected by TGA, WHO GMP, KFDA, PMDA, Health Canada, ANVISA & USFDA.
  • Planning USDMF by December 2024.

To learn more about our API offerings, please read the Tech sheet on Daprodustat API by filling out the contact form below.

Note: *Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.